Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT07251712
Recruiting Phase 1

Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet

NCT07251712 · tracked via the Priya Life Science UK tracker
Sponsor
Galmed Pharmaceuticals Ltd
Phase
Phase 1
Started
2025-12-25
Last updated
2026-09-10

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

Aramchol

Aramchol: Aramchol tablet at 2 different single doses

Study summary

Evaluate the exposure of of Aramchol from 2 different single doses of Aramchol meglumine tablet and to compare the exposure of steady state from a selected dose of Aramchol meglumine tablet.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female healthy volunteers with body mass index (BMI) in the range of 18-30.9 kg/ m2 inclusive * Deemed healthy on the basis of clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine * Agree to follow-up the contraception requirements of the trial * Able to give fully informed written consent Exclusion Criteria: * Females of reproductive potential who are pregnant or lactating * Positive tests for hepatitis B, C or HIV * History of sever adverse reaction to any drug * Known sensitivity to drug medication * Drug or alcohol abuse * Smoking in the 3 months prior the study * Clinically relevant abnormal lab results, medical history or concurrent medical condition * Evidence of acute or chronic disease * Inability to adhere to study requirements

Primary outcome measure(s)

  • Maximum observed peak concentration (Cmax) of Aramchol — 2 months
    Blood samples will be collected for pharmacokinetics characterization. Cmax will be calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.
  • Time to reach maximum concentration (Tmax) of Aramchol — 2 months
    Blood samples will be collected for pharmacokinetics characterization. Tmax will be calculated from plasma concentration-time data using non-compartmental methods based on the actual time of sample collection and summarized using descriptive statistics
  • Area under the plasma curve (AUC) of Aramchol — 2 months
    Blood samples will be collected for pharmacokinetics characterization. AUC of Aramchol will be calculated from plasma concentration-time data using non-compartmental methods and summarized using descriptive statistics.

Trial sites (1)

FacilityCityRegionStatus
Hammersmith Medicines Research (HMR) London United Kingdom Recruiting

Other trials for the same condition

Blood Testing at Entia Enrolling by invitation
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies Recruiting
A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways Recruiting
Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants Active, not recruiting
Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07251712 on ClinicalTrials.gov ↗ ← All trials in the UK